{"id":2497,"date":"2024-05-08T20:44:30","date_gmt":"2024-05-08T20:44:30","guid":{"rendered":"https:\/\/stoxpo.com\/?p=2497"},"modified":"2024-05-08T20:44:31","modified_gmt":"2024-05-08T20:44:31","slug":"advancing-cancer-therapy-cytomxs-positive-clinical-data-and-future-milestones","status":"publish","type":"post","link":"https:\/\/stoxpo.com\/index.php\/2024\/05\/08\/advancing-cancer-therapy-cytomxs-positive-clinical-data-and-future-milestones\/","title":{"rendered":"Advancing Cancer Therapy: CytomX&#8217;s Positive Clinical Data and Future Milestones"},"content":{"rendered":"\n<h4 class=\"wp-block-heading\">Insights into CytomX&#8217;s Innovative Therapeutic Pipeline and Financial Performance<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">CytomX Therapeutics (CTMX), a pioneering player in the oncology therapeutics domain, has unveiled promising initial Phase 1a dose escalation data for its monotherapy CX-904, marking a significant stride in the fight against solid tumors. Alongside, the company has reached crucial milestones in its CX-2051 and CX-801 programs, reinforcing its commitment to delivering novel, potent therapies for cancer patients.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The announcement of favorable Phase 1a clinical data for CX-904 underscores CytomX&#8217;s leadership and continuous innovation in developing masked, conditionally activated biologics. With CX-904 demonstrating a favorable safety profile and encouraging anti-cancer activity, the company is poised to explore its potential in addressing critical areas of unmet need in cancer treatment.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In parallel, the advancement of CX-2051, an EpCAM-targeting PROBODY\u00ae ADC, and CX-801, an interferon alpha-2b PROBODY\u00ae cytokine, further solidifies CytomX&#8217;s position in the oncology therapeutics landscape. By leveraging innovative approaches and strategic collaborations, such as the clinical collaboration agreement with Merck for evaluating CX-801 in combination with KEYTRUDA\u00ae, CytomX aims to maximize the therapeutic impact of its pipeline candidates.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Sean McCarthy, D.Phil., CEO, and chairman of CytomX, expressed confidence in the company&#8217;s trajectory, emphasizing the significance of the recent developments in advancing cancer therapy. With a data-rich period ahead, marked by key readouts from its multi-modality PROBODY\u00ae therapeutic pipeline, CytomX is poised to make substantial progress in addressing the evolving needs of cancer patients.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Amidst these clinical advancements, CytomX has also achieved significant financial milestones, with total revenue reaching $41.5 million for the first quarter of 2024. The company&#8217;s robust financial position, coupled with its strategic collaborations and ongoing R&amp;D partnerships, positions it favorably to execute its ambitious agenda of delivering innovative cancer therapies.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">As CytomX continues to make strides in its R&amp;D endeavors and collaborations, investors and stakeholders eagerly anticipate further updates on its pipeline candidates and the potential impact on cancer treatment paradigms. With a relentless commitment to scientific excellence and therapeutic innovation, CytomX remains at the forefront of driving meaningful progress in the fight against cancer.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">You might like this article:<a href=\"https:\/\/stoxpo.com\/index.php\/2024\/05\/08\/ubers-q1-report-revenue-beats-expectations-net-loss-widens\/\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-vivid-cyan-blue-color\">Uber\u2019s Q1 Report: Revenue Beats Expectations, Net Loss Widens<\/mark><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Insights into CytomX&#8217;s Innovative Therapeutic Pipeline and Financial Performance CytomX Therapeutics (CTMX), a pioneering player in the oncology therapeutics domain, has unveiled promising initial Phase 1a dose escalation data for its monotherapy CX-904, marking a significant stride in the fight against solid tumors. Alongside, the company has reached crucial milestones in its CX-2051 and CX-801 [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":1429,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jnews-multi-image_gallery":[],"jnews_single_post":{"subtitle":"","format":"standard","video":"","gallery":"","source_name":"","source_url":"","via_name":"","via_url":"","override_template":"0","override":[{"template":"8","single_blog_custom":"","parallax":"1","fullscreen":"1","layout":"right-sidebar-narrow","sidebar":"author","second_sidebar":"single-right","sticky_sidebar":"1","share_position":"top","share_float_style":"share-monocrhome","show_share_counter":"0","show_view_counter":"0","show_featured":"1","show_post_meta":"1","show_post_author":"1","show_post_author_image":"0","show_post_date":"1","post_date_format":"default","post_date_format_custom":"Y\/m\/d","show_post_category":"1","show_post_reading_time":"1","post_reading_time_wpm":"300","show_zoom_button":"0","zoom_button_out_step":"2","zoom_button_in_step":"3","show_post_tag":"1","show_prev_next_post":"1","show_popup_post":"1","number_popup_post":"1","show_author_box":"0","show_post_related":"1","show_inline_post_related":"0"}],"override_image_size":"0","image_override":[{"single_post_thumbnail_size":"crop-500","single_post_gallery_size":"crop-500"}],"trending_post":"0","trending_post_position":"meta","trending_post_label":"Trending","sponsored_post":"0","sponsored_post_label":"Sponsored by","sponsored_post_name":"","sponsored_post_url":"","sponsored_post_logo_enable":"0","sponsored_post_logo":"","sponsored_post_desc":"","disable_ad":"0"},"jnews_primary_category":{"id":"","hide":""},"jnews_social_meta":{"fb_title":"","fb_description":"","fb_image":"","twitter_title":"","twitter_description":"","twitter_image":""},"jnews_override_counter":{"override_view_counter":"0","view_counter_number":"0","override_share_counter":"0","share_counter_number":"0","override_like_counter":"0","like_counter_number":"0","override_dislike_counter":"0","dislike_counter_number":"0"},"jnews_post_split":{"enable_post_split":"0","post_split":[{"template":"1","tag":"h2","numbering":"asc","mode":"normal","first":"0","enable_toc":"0","toc_type":"normal"}]},"footnotes":""},"categories":[309,359],"tags":[419,420,421,416,436],"coauthors":[],"class_list":["post-2497","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pharmaceuticals","category-small-cap","tag-breaking","tag-earnings","tag-growth","tag-movers","tag-trials"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Advancing Cancer Therapy: CytomX&#039;s Positive Clinical Data and Future Milestones - Stoxpo<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/stoxpo.com\/index.php\/2024\/05\/08\/advancing-cancer-therapy-cytomxs-positive-clinical-data-and-future-milestones\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Advancing Cancer Therapy: CytomX&#039;s Positive Clinical Data and Future Milestones - Stoxpo\" \/>\n<meta property=\"og:description\" content=\"Insights into CytomX&#8217;s Innovative Therapeutic Pipeline and Financial Performance CytomX Therapeutics (CTMX), a pioneering player in the oncology therapeutics domain, has unveiled promising initial Phase 1a dose escalation data for its monotherapy CX-904, marking a significant stride in the fight against solid tumors. Alongside, the company has reached crucial milestones in its CX-2051 and CX-801 [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/stoxpo.com\/index.php\/2024\/05\/08\/advancing-cancer-therapy-cytomxs-positive-clinical-data-and-future-milestones\/\" \/>\n<meta property=\"og:site_name\" content=\"Stoxpo\" \/>\n<meta property=\"article:published_time\" content=\"2024-05-08T20:44:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-05-08T20:44:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-chokniti-khongchum-2280571-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1709\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Luca Blaumann\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Luca Blaumann\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/05\\\/08\\\/advancing-cancer-therapy-cytomxs-positive-clinical-data-and-future-milestones\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/05\\\/08\\\/advancing-cancer-therapy-cytomxs-positive-clinical-data-and-future-milestones\\\/\"},\"author\":{\"name\":\"Luca Blaumann\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/person\\\/031a96817fc4447b1046e0a10baad806\"},\"headline\":\"Advancing Cancer Therapy: CytomX&#8217;s Positive Clinical Data and Future Milestones\",\"datePublished\":\"2024-05-08T20:44:30+00:00\",\"dateModified\":\"2024-05-08T20:44:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/05\\\/08\\\/advancing-cancer-therapy-cytomxs-positive-clinical-data-and-future-milestones\\\/\"},\"wordCount\":372,\"publisher\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/05\\\/08\\\/advancing-cancer-therapy-cytomxs-positive-clinical-data-and-future-milestones\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/pexels-chokniti-khongchum-2280571-scaled.jpg\",\"keywords\":[\"Breaking\",\"Earnings\",\"Growth\",\"Movers\",\"Trials\"],\"articleSection\":[\"Pharmaceuticals\",\"Small-Cap\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/05\\\/08\\\/advancing-cancer-therapy-cytomxs-positive-clinical-data-and-future-milestones\\\/\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/05\\\/08\\\/advancing-cancer-therapy-cytomxs-positive-clinical-data-and-future-milestones\\\/\",\"name\":\"Advancing Cancer Therapy: CytomX's Positive Clinical Data and Future Milestones - Stoxpo\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/05\\\/08\\\/advancing-cancer-therapy-cytomxs-positive-clinical-data-and-future-milestones\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/05\\\/08\\\/advancing-cancer-therapy-cytomxs-positive-clinical-data-and-future-milestones\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/pexels-chokniti-khongchum-2280571-scaled.jpg\",\"datePublished\":\"2024-05-08T20:44:30+00:00\",\"dateModified\":\"2024-05-08T20:44:31+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/05\\\/08\\\/advancing-cancer-therapy-cytomxs-positive-clinical-data-and-future-milestones\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/05\\\/08\\\/advancing-cancer-therapy-cytomxs-positive-clinical-data-and-future-milestones\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/05\\\/08\\\/advancing-cancer-therapy-cytomxs-positive-clinical-data-and-future-milestones\\\/#primaryimage\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/pexels-chokniti-khongchum-2280571-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/pexels-chokniti-khongchum-2280571-scaled.jpg\",\"width\":2560,\"height\":1709,\"caption\":\"chemistry-2\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/05\\\/08\\\/advancing-cancer-therapy-cytomxs-positive-clinical-data-and-future-milestones\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/stoxpo.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Advancing Cancer Therapy: CytomX&#8217;s Positive Clinical Data and Future Milestones\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#website\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/\",\"name\":\"Stoxpo\",\"description\":\"Stock Market &amp; Financial News\",\"publisher\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/stoxpo.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\",\"name\":\"Stoxpo\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/4q4p91-LogoMakr.png\",\"contentUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/4q4p91-LogoMakr.png\",\"width\":250,\"height\":250,\"caption\":\"Stoxpo\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/person\\\/031a96817fc4447b1046e0a10baad806\",\"name\":\"Luca Blaumann\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g90dbb3a40c7379bca26d2b3dc92b368b\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g\",\"caption\":\"Luca Blaumann\"},\"description\":\"Luca is a proficient stock market reporter with a passion for dissecting complex market dynamics and uncovering transformative industry developments. With years of experience in leading editorial teams and overseeing coverage of the stock market and publicly traded companies, Luca has honed the ability to translate finance jargon into easily digestible articles. For tips and inquiries, reach out to Luca at tips@stoxpo.com.\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/author\\\/luca-blaumann\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Advancing Cancer Therapy: CytomX's Positive Clinical Data and Future Milestones - Stoxpo","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/stoxpo.com\/index.php\/2024\/05\/08\/advancing-cancer-therapy-cytomxs-positive-clinical-data-and-future-milestones\/","og_locale":"en_US","og_type":"article","og_title":"Advancing Cancer Therapy: CytomX's Positive Clinical Data and Future Milestones - Stoxpo","og_description":"Insights into CytomX&#8217;s Innovative Therapeutic Pipeline and Financial Performance CytomX Therapeutics (CTMX), a pioneering player in the oncology therapeutics domain, has unveiled promising initial Phase 1a dose escalation data for its monotherapy CX-904, marking a significant stride in the fight against solid tumors. Alongside, the company has reached crucial milestones in its CX-2051 and CX-801 [&hellip;]","og_url":"https:\/\/stoxpo.com\/index.php\/2024\/05\/08\/advancing-cancer-therapy-cytomxs-positive-clinical-data-and-future-milestones\/","og_site_name":"Stoxpo","article_published_time":"2024-05-08T20:44:30+00:00","article_modified_time":"2024-05-08T20:44:31+00:00","og_image":[{"width":2560,"height":1709,"url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-chokniti-khongchum-2280571-scaled.jpg","type":"image\/jpeg"}],"author":"Luca Blaumann","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Luca Blaumann","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/stoxpo.com\/index.php\/2024\/05\/08\/advancing-cancer-therapy-cytomxs-positive-clinical-data-and-future-milestones\/#article","isPartOf":{"@id":"https:\/\/stoxpo.com\/index.php\/2024\/05\/08\/advancing-cancer-therapy-cytomxs-positive-clinical-data-and-future-milestones\/"},"author":{"name":"Luca Blaumann","@id":"https:\/\/stoxpo.com\/#\/schema\/person\/031a96817fc4447b1046e0a10baad806"},"headline":"Advancing Cancer Therapy: CytomX&#8217;s Positive Clinical Data and Future Milestones","datePublished":"2024-05-08T20:44:30+00:00","dateModified":"2024-05-08T20:44:31+00:00","mainEntityOfPage":{"@id":"https:\/\/stoxpo.com\/index.php\/2024\/05\/08\/advancing-cancer-therapy-cytomxs-positive-clinical-data-and-future-milestones\/"},"wordCount":372,"publisher":{"@id":"https:\/\/stoxpo.com\/#organization"},"image":{"@id":"https:\/\/stoxpo.com\/index.php\/2024\/05\/08\/advancing-cancer-therapy-cytomxs-positive-clinical-data-and-future-milestones\/#primaryimage"},"thumbnailUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-chokniti-khongchum-2280571-scaled.jpg","keywords":["Breaking","Earnings","Growth","Movers","Trials"],"articleSection":["Pharmaceuticals","Small-Cap"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/stoxpo.com\/index.php\/2024\/05\/08\/advancing-cancer-therapy-cytomxs-positive-clinical-data-and-future-milestones\/","url":"https:\/\/stoxpo.com\/index.php\/2024\/05\/08\/advancing-cancer-therapy-cytomxs-positive-clinical-data-and-future-milestones\/","name":"Advancing Cancer Therapy: CytomX's Positive Clinical Data and Future Milestones - Stoxpo","isPartOf":{"@id":"https:\/\/stoxpo.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/stoxpo.com\/index.php\/2024\/05\/08\/advancing-cancer-therapy-cytomxs-positive-clinical-data-and-future-milestones\/#primaryimage"},"image":{"@id":"https:\/\/stoxpo.com\/index.php\/2024\/05\/08\/advancing-cancer-therapy-cytomxs-positive-clinical-data-and-future-milestones\/#primaryimage"},"thumbnailUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-chokniti-khongchum-2280571-scaled.jpg","datePublished":"2024-05-08T20:44:30+00:00","dateModified":"2024-05-08T20:44:31+00:00","breadcrumb":{"@id":"https:\/\/stoxpo.com\/index.php\/2024\/05\/08\/advancing-cancer-therapy-cytomxs-positive-clinical-data-and-future-milestones\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/stoxpo.com\/index.php\/2024\/05\/08\/advancing-cancer-therapy-cytomxs-positive-clinical-data-and-future-milestones\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/stoxpo.com\/index.php\/2024\/05\/08\/advancing-cancer-therapy-cytomxs-positive-clinical-data-and-future-milestones\/#primaryimage","url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-chokniti-khongchum-2280571-scaled.jpg","contentUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-chokniti-khongchum-2280571-scaled.jpg","width":2560,"height":1709,"caption":"chemistry-2"},{"@type":"BreadcrumbList","@id":"https:\/\/stoxpo.com\/index.php\/2024\/05\/08\/advancing-cancer-therapy-cytomxs-positive-clinical-data-and-future-milestones\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/stoxpo.com\/"},{"@type":"ListItem","position":2,"name":"Advancing Cancer Therapy: CytomX&#8217;s Positive Clinical Data and Future Milestones"}]},{"@type":"WebSite","@id":"https:\/\/stoxpo.com\/#website","url":"https:\/\/stoxpo.com\/","name":"Stoxpo","description":"Stock Market &amp; Financial News","publisher":{"@id":"https:\/\/stoxpo.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/stoxpo.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/stoxpo.com\/#organization","name":"Stoxpo","url":"https:\/\/stoxpo.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/stoxpo.com\/#\/schema\/logo\/image\/","url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/4q4p91-LogoMakr.png","contentUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/4q4p91-LogoMakr.png","width":250,"height":250,"caption":"Stoxpo"},"image":{"@id":"https:\/\/stoxpo.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/stoxpo.com\/#\/schema\/person\/031a96817fc4447b1046e0a10baad806","name":"Luca Blaumann","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g90dbb3a40c7379bca26d2b3dc92b368b","url":"https:\/\/secure.gravatar.com\/avatar\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g","caption":"Luca Blaumann"},"description":"Luca is a proficient stock market reporter with a passion for dissecting complex market dynamics and uncovering transformative industry developments. With years of experience in leading editorial teams and overseeing coverage of the stock market and publicly traded companies, Luca has honed the ability to translate finance jargon into easily digestible articles. For tips and inquiries, reach out to Luca at tips@stoxpo.com.","url":"https:\/\/stoxpo.com\/index.php\/author\/luca-blaumann\/"}]}},"_links":{"self":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/2497","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/comments?post=2497"}],"version-history":[{"count":1,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/2497\/revisions"}],"predecessor-version":[{"id":2498,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/2497\/revisions\/2498"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media\/1429"}],"wp:attachment":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media?parent=2497"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/categories?post=2497"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/tags?post=2497"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/coauthors?post=2497"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}